Treatment of inflammatory bowel disease by inhibiting binding and/or signalling through alpha4beta7 and its ligands and MAdCAM
AssigneeMillennium Pharmaceuticals, Inc.
InventorsDouglas J. Ringler, Dominic Picarella, Walter Newman
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of individuals suffering from a disease associated with leukocyte recruitment to the gastrointestinal tract or other tissues as a result of binding of leukocytes to gut-associated endothelium expressing the molecule MAdCAM (such as inflammatory bowel disease), comprising administering to the individual an effective amount of an antibody which inhibits the binding of leukocytes to endothelial MAdCAM.
Claims37
A method for treating an individual having a disease associated with leukocyte recruitment to the gastrointestinal tract or other tissues as a result of binding of leukocytes to gut-associated endothelium expressing the molecule MAdCAM, comprising:
- administering to the individual an effective amount of an antibody which inhibits the binding of leukocytes to endothelial MAdCAM.
A method for treating inflammatory bowel disease in an individual comprising administering to the individual an effective amount of an antibody which binds endothelial MAdCAM or the α4β7 integrin.
Dependencies are inferred from the claim text.